Patients With "ASA 3" DesignationPhase 2NCT02282891
Compare the Effect of Propofol vs. "Ketofol" on Hemodynamic Stability During Induction of General Anesthesia
A Phase 2 study testing Propofol and Propofol-Ketamine in people with Patients With "ASA 3" Designation, run by Yale University at 1 site in United States.
Trial summary
The purpose of this study is to compare the hemodynamic effects of a standardized induction of general anesthesia with either propofol or ketofol in patients with physical status classification ASA 3. The study will be a double blinded, randomized controlled trial (RCT) with two arms of treatment groups. Read more about this study
- Who is it for?
- Ages 18 to 80 years
- Conditions the study is for
- Patients With "ASA 3" Designation
- What is being tested?
- Propofol and Propofol-Ketamine
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 0 participants
- Where
- 1 siteUnited States
- Study dates
- Jan 2015to Aug 2016
- Phase
- Phase 2
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 80 years
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Patients age 18-80 scheduled for elective surgery
- Physical status ASA 3.
Who cannot join
- Patients with a physical status of ASA 1,2, 4 or 5,
- Prior adverse reaction to propofol, ketamine or both
Trial locations and contacts
1 site in 1 country.
United States1 site
Yale New Haven Hospital
New Haven, Connecticut, 06519
About this study
Official title: A Randomized-Controlled Trial to Compare the Effect of Propofol vs. "Ketofol" on Hemodynamic Stability During Induction of General Anesthesia
The purpose of this study is to compare the hemodynamic effects of a standardized induction of general anesthesia with either propofol or ketofol in patients with physical status classification ASA 3. The study will be a double blinded, randomized controlled trial (RCT) with two arms of treatment groups. One arm will consist of induction of general anesthesia using a mixture of 1.5mg/kg:0.75mg/kg Propofol/ketamine (ketofol) and the induction dose will be 1.5mg/kg of propofol and 0.75mg/kg of ketamine; the second arm will consist of induction of general anesthesia using propofol 2mg/kg. The primary outcome of the intervention will consist of hemodynamic changes during the first 30 minutes after induction of general anesthesia.
Read the detailed description
The anesthetic agent propofol can result in hypotension when used for induction of general anesthesia. Recent trials suggest that even a short duration of hypotension during induction of anesthesia can adversely affect organ function and overall outcome.1 To overcome the hypotensive effect of propofol, ketamine, which has sympathomimetic effects, has been combined with propofol to produce a mixture labeled "ketofol", which has been used both for procedural sedation and induction of general anesthesia. Clinical trials have shown that ketofol can attenuate the hypotensive effects of propofol during procedural sedation or induction of general anesthesia in patients whose physical status is 1 or 2 according to the American Society of Anesthesiologists (ASA 1-2), i.e., healthy patients or those with mild-moderate systemic illness.2,3 Clinically, it is important to demonstrate the efficacy of ketofol in attenuating hypotensive effects of propofol in sicker patients, i.e., patients with physical status ASA 3. The purpose of this study is to compare the hemodynamic effects of a standardized induction of general anesthesia with either propofol or ketofol in patients with physical status classification ASA 3. The study will be a double blinded, randomized controlled trial (RCT) with two arms of treatment groups. One arm will consist of induction of general anesthesia using a mixture of 1.5mg/kg:0.75mg/kg Propofol/ketamine (ketofol) and the induction dose will be 1.5mg/kg of propfol and 0.75mg/kg of ketamine; the second arm will consist of induction of general anesthesia using propofol 2mg/kg. The primary outcome of the intervention will consist of hemodynamic changes during the first 30 minutes after induction of general anesthesia.
Baseline demographics collected for each patient will include:
- age
- sex
- ASA physical status
- Hx of HTN
- Hx of PONV
- Preoperative pain score
The standardized induction of anesthesia will consist of intravenous administration of midazolam 0.04mg/kg, lidocaine 1 mg/kg, fentanyl 1-2 mcg/kg, glycopyrrolate 0.004 mg/kg, an unlabeled pre-prepared, covered syringe which will be prepared by the Yale Anesthesia satellite pharmacist containing either propofol 2mg/kg or a mixture propofol 1.5mg/kg and ketamine 0.75mg/kg, the amount of which will be pre-determined based on the patient weight, and rocuronium 0.6 mg/kg. A backup 10cc syringe of the study drug will be available as well if the initial dose is inadequate. The choice of propofol and ketamine dosing is based on a study cited earlier by Smischney et al in 2012 that addresses ASA 1-2 patients undergoing induction of general anesthesia. Endotracheal intubation will take place after adequate muscle relaxation has been determined using fade of train of four on a nerve stimulator placed over the ulnar nerve. Additional medication to facilitate induction will be used according to the judgment of the anesthesia provider with a backup syringe of the same study drug. Inhalational anesthesia will be administered after confirmation of endotracheal intubation. Treatment of hypotension will be according to the anesthesia provider. Amounts of intravenous fluids as well as doses of vasopressor that are used during induction and in the subsequent 30 minutes after endotracheal intubation will be obtained from the anesthesia record.
The first blood pressure (BP) upon arrival to the operating room before any anesthetic medications are administered will be the reference (baseline) blood pressure. BP will be measured every 1 minute from one minute before induction until 30 minutes after endotracheal intubation.
The primary outcome of the study will be the number of time points during which the blood pressure was below 20% of the baseline BP. Secondary outcomes will include:
- Severity of hypotension as determined by the gradient of each blood pressure measurement from the baseline BP.
- The total dosage of vasopressors administered during induction and up to 30 minutes after endotracheal intubation
- The total amount of IV fluids administered during induction and up to 30 minutes after endotracheal intubation.
- The total amount of additional medications used during induction and up to 30 minutes after endotracheal intubation.
- Total intraoperative as well as postoperative opioid dosage used.
- Presence or absence of PONV and severity
- Intraoperative prophylaxis and postoperative treatment of PONV
- Conditions
- Patients With "ASA 3" Designation
- Being tested
- Propofol, Propofol-Ketamine
- Keywords
- propofol, ketofol
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
PropofolDrug
Also called Diprivan
Induction of general anesthesia using propofol 2mg/kg
Propofol-KetamineDrug
Also called ketofol
Induction of general anesthesia using a mixture of 1.5 mg/kg:0.75 mg/kg propofol/ketamine
| Study group | Role | What they receive |
|---|---|---|
| Propofol | Active comparator | Induction of general Anesthesia using propofol 2mg/kg Receives: Drug: Propofol |
| Propofol/Ketamine (ketofol) | Experimental | Induction of general anesthesia using a mixture of 1.5mg/kg:0.75mg/kg Propofol/ketamine Receives: Drug: Propofol-Ketamine |
What is being measured
The primary outcome is the main question the study is designed to answer.
Number of time points during which blood pressure was below 20% of baseline BP
The number of time points during which the blood pressure was below 20% of the baseline BP. The first blood pressure upon arrival to the operating room before any anesthetic medications are administered will be the reference (baseline) blood pressure. BP will be measured every 1 minute from one minute before induction until 30 minutes after endotracheal intubation.
Measured: up to 30 minutes after intubation
Secondary outcomes (7)
Severity of hypotension
As determined by the gradient of each blood pressure measurement from the baseline BP
Measured: up to 30 minutes after intubation
Total dosage of vasopressors administered
The total dosage of vasopressors administered during induction and up to 30 minutes after endotracheal intubation
Measured: up to 30 minutes after intubation
Amount of IV fluids administered
The total amount of IV fluids administered during induction and up to 30 minutes after endotracheal intubation.
Measured: up to 30 minutes after intubation
Additional Medication Usage
The total amount of additional medications used during induction and up to 30 minutes after endotracheal intubation.
Measured: up to 30 minutes after intubation
Total Opioid Dosage Used
Total intraoperative as well as postoperative opioid dosage used.
Measured: up to 30 minutes after intubation
Post Operative Nausea and Vomiting (PONV) Severity
Presence or absence of PONV and severity within 72 hours of surgery
Measured: 72 hours post surgery
Treatment of Post Operative Nausea and Vomiting (PONV)
Number and dose of anti-emetics given within 72 hours of surgery
Measured: 72 hours post surgery
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted5 Nov 2014 (estimated)
- Study startJan 2015
- Primary completionJan 2016 (estimated)
- Study completionAug 2016
Why it stopped: No subjects were ever recruited and enrolled.
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Patients With "ASA 3" DesignationStudies of the same condition, open and under way.
- More trials run by Yale UniversityThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase 2
- Primary purpose
- Supportive care
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Quadruple blind
- Who is masked
- Participant, Care provider, Investigator, Outcomes assessor
- Enrolment
- 0 participants (actual)
Sponsor and investigators
- Lead sponsor
- Yale University
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor
- Investigators
- Jamel P Ortoleva, MD, Principal investigator, Yale UniversityJean Charchaflieh, MD,MPH,DrPH, Principal investigator, Yale University
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT02282891
- Sponsor's protocol ID
- 1406014189
- Status last verified
- Dec 2016
- First submitted
- 31 Oct 2014
- Last updated
- 15 Dec 2016
- Results posted
- No
- Data monitoring committee
- No
Study at a glance
From the registry record, last updated by the sponsor on 15 Dec 2016. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- A Randomized-Controlled Trial to Compare the Effect of Propofol vs. "Ketofol" on Hemodynamic Stability During Induction of General Anesthesia
- ClinicalTrials.gov ID
- NCT02282891
- Acronym / sponsor ID
- 1406014189
- Conditions
- Patients With "ASA 3" Designation
- Keywords
- propofol, ketofol
- Phase
- Phase 2
- Study type
- Interventional
- Recruitment status
- WithdrawnReason stopped: No subjects were ever recruited and enrolled.
- Enrolment
- 0 participants (actual)
- Lead sponsor
- Yale UniversityUniversity, hospital or other
- Study start
- Jan 2015
- Primary completion
- Jan 2016 (estimated)
- Study completion
- Aug 2016 (actual)
- First posted
- 5 Nov 2014 (estimated)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The purpose of this study is to compare the hemodynamic effects of a standardized induction of general anesthesia with either propofol or ketofol in patients with physical status classification ASA 3. The study will be a double blinded, randomized controlled trial (RCT) with two arms of treatment groups. One arm will consist of induction of general anesthesia using a mixture of 1.5mg/kg:0.75mg/kg Propofol/ketamine (ketofol) and the induction dose will be 1.5mg/kg of propofol and 0.75mg/kg of ketamine; the second arm will consist of induction of general anesthesia using propofol 2mg/kg. The primary outcome of the intervention will consist of hemodynamic changes during the first 30 minutes after induction of general anesthesia.
Detailed description
The anesthetic agent propofol can result in hypotension when used for induction of general anesthesia. Recent trials suggest that even a short duration of hypotension during induction of anesthesia can adversely affect organ function and overall outcome.1 To overcome the hypotensive effect of propofol, ketamine, which has sympathomimetic effects, has been combined with propofol to produce a mixture labeled "ketofol", which has been used both for procedural sedation and induction of general anesthesia. Clinical trials have shown that ketofol can attenuate the hypotensive effects of propofol during procedural sedation or induction of general anesthesia in patients whose physical status is 1 or 2 according to the American Society of Anesthesiologists (ASA 1-2), i.e., healthy patients or those with mild-moderate systemic illness.2,3 Clinically, it is important to demonstrate the efficacy of ketofol in attenuating hypotensive effects of propofol in sicker patients, i.e., patients with physical status ASA 3. The purpose of this study is to compare the hemodynamic effects of a standardized induction of general anesthesia with either propofol or ketofol in patients with physical status classification ASA 3. The study will be a double blinded, randomized controlled trial (RCT) with two arms of treatment groups. One arm will consist of induction of general anesthesia using a mixture of 1.5mg/kg:0.75mg/kg Propofol/ketamine (ketofol) and the induction dose will be 1.5mg/kg of propfol and 0.75mg/kg of ketamine; the second arm will consist of induction of general anesthesia using propofol 2mg/kg. The primary outcome of the intervention will consist of hemodynamic changes during the first 30 minutes after induction of general anesthesia.
Baseline demographics collected for each patient will include:
- age
- sex
- ASA physical status
- Hx of HTN
- Hx of PONV
- Preoperative pain score
The standardized induction of anesthesia will consist of intravenous administration of midazolam 0.04mg/kg, lidocaine 1 mg/kg, fentanyl 1-2 mcg/kg, glycopyrrolate 0.004 mg/kg, an unlabeled pre-prepared, covered syringe which will be prepared by the Yale Anesthesia satellite pharmacist containing either propofol 2mg/kg or a mixture propofol 1.5mg/kg and ketamine 0.75mg/kg, the amount of which will be pre-determined based on the patient weight, and rocuronium 0.6 mg/kg. A backup 10cc syringe of the study drug will be available as well if the initial dose is inadequate. The choice of propofol and ketamine dosing is based on a study cited earlier by Smischney et al in 2012 that addresses ASA 1-2 patients undergoing induction of general anesthesia. Endotracheal intubation will take place after adequate muscle relaxation has been determined using fade of train of four on a nerve stimulator placed over the ulnar nerve. Additional medication to facilitate induction will be used according to the judgment of the anesthesia provider with a backup syringe of the same study drug. Inhalational anesthesia will be administered after confirmation of endotracheal intubation. Treatment of hypotension will be according to the anesthesia provider. Amounts of intravenous fluids as well as doses of vasopressor that are used during induction and in the subsequent 30 minutes after endotracheal intubation will be obtained from the anesthesia record.
The first blood pressure (BP) upon arrival to the operating room before any anesthetic medications are administered will be the reference (baseline) blood pressure. BP will be measured every 1 minute from one minute before induction until 30 minutes after endotracheal intubation.
The primary outcome of the study will be the number of time points during which the blood pressure was below 20% of the baseline BP. Secondary outcomes will include:
- Severity of hypotension as determined by the gradient of each blood pressure measurement from the baseline BP.
- The total dosage of vasopressors administered during induction and up to 30 minutes after endotracheal intubation
- The total amount of IV fluids administered during induction and up to 30 minutes after endotracheal intubation.
- The total amount of additional medications used during induction and up to 30 minutes after endotracheal intubation.
- Total intraoperative as well as postoperative opioid dosage used.
- Presence or absence of PONV and severity
- Intraoperative prophylaxis and postoperative treatment of PONV
Study design
- Primary purpose
- Supportive care
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Quadruple blind (participant, care provider, investigator, outcomes assessor)
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| Propofol | Active comparator | Drug: PropofolInduction of general Anesthesia using propofol 2mg/kg |
| Propofol/Ketamine (ketofol) | Experimental | Drug: Propofol-KetamineInduction of general anesthesia using a mixture of 1.5mg/kg:0.75mg/kg Propofol/ketamine |
Who may qualify
- Ages
- 18 to 80 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (2 listed)
- Patients age 18-80 scheduled for elective surgery
- Physical status ASA 3.
Key exclusion criteria (2 listed)
- Patients with a physical status of ASA 1,2, 4 or 5,
- Prior adverse reaction to propofol, ketamine or both
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| PropofolAlso: DiprivanInduction of general anesthesia using propofol 2mg/kg | Drug | Propofol |
| Propofol-KetamineAlso: ketofolInduction of general anesthesia using a mixture of 1.5 mg/kg:0.75 mg/kg propofol/ketamine | Drug | Propofol/Ketamine (ketofol) |
Primary outcome
Number of time points during which blood pressure was below 20% of baseline BP
Time frame: up to 30 minutes after intubation
The number of time points during which the blood pressure was below 20% of the baseline BP. The first blood pressure upon arrival to the operating room before any anesthetic medications are administered will be the reference (baseline) blood pressure. BP will be measured every 1 minute from one minute before induction until 30 minutes after endotracheal intubation.
7 secondary outcomes
Severity of hypotension
Time frame: up to 30 minutes after intubation
Total dosage of vasopressors administered
Time frame: up to 30 minutes after intubation
Amount of IV fluids administered
Time frame: up to 30 minutes after intubation
Additional Medication Usage
Time frame: up to 30 minutes after intubation
Total Opioid Dosage Used
Time frame: up to 30 minutes after intubation
Post Operative Nausea and Vomiting (PONV) Severity
Time frame: 72 hours post surgery
Treatment of Post Operative Nausea and Vomiting (PONV)
Time frame: 72 hours post surgery
Results and safety
The study was withdrawn before enrolling participants, so there are no results.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 15 Dec 2016.
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Jamel P Ortoleva, MD principal investigator
Yale University
Jean Charchaflieh, MD,MPH,DrPH principal investigator
Yale University
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A Phase 2 study testing Propofol and Propofol-Ketamine in people with Patients With "ASA 3" Designation, run by Yale University at 1 site in United States.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 2 inclusion and 2 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: withdrawn, as of the sponsor's last update on 15 Dec 2016. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in United States. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
What does this phase mean?
Phase 2 studies give the treatment to a larger group to see whether it has the intended effect and to keep checking safety.
Not every study follows the same path, and some studies (observational studies, device studies) have no phase.
Are results available for this study?
The study was withdrawn before enrolling participants, so there are no results.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Number of time points during which blood pressure was below 20% of baseline BP (time frame: up to 30 minutes after intubation). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 15 Dec 2016.